Vaccine Adjuvants Market - Global Vaccine Adjuvants Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2032 -

Description

The worldwide vaccine adjuvants market is on a trajectory of remarkable growth, with projections estimating a valuation of US$ 4.33 billion by 2032, up from US$ 1.69 billion in 2025. The market is forecasted to expand at a CAGR of 14.3% from 2025 to 2032, propelled by increasing occurrences of infectious diseases and continuous advancements in adjuvant technologies.

Market Dynamics

The rising prevalence of infectious diseases such as COVID-19, malaria, and dengue is escalating the need for enhanced vaccines, boosting demand for innovative adjuvants.
Advancements in lipid nanoparticles and immune modulators are contributing to better vaccine efficiency and safety.
mRNA vaccine technology, which heavily relies on novel adjuvants, is significantly influencing market expansion.
Government-backed immunization initiatives are fostering the development and large-scale adoption of vaccine adjuvants.
Pharmaceutical firms are making substantial investments in next-generation adjuvants to combat emerging health threats.
Regulatory approvals from entities like the FDA and EMA remain pivotal in supporting market expansion.
A move toward personalized immunization is unlocking new prospects for adjuvants tailored for specific patient categories.

Market Growth Drivers

1. Surge in Infectious Diseases

Rising cases of influenza, malaria, dengue, and COVID-19 are driving the need for advanced vaccine formulations.
In 2024, over 14 million dengue infections and more than 10,000 dengue-related fatalities were recorded globally.
Vector-borne illnesses account for over 17% of all infectious diseases, leading to approximately 700,000 deaths annually.
Vaccine adjuvants strengthen immune response, offering long-lasting and broad protection.

2. Expanding Immunization Programs and Government Funding

Governments across the globe are intensifying investments in vaccination initiatives, accelerating adjuvant adoption.
Organizations such as WHO, UNICEF, and Gavi support extensive immunization drives, particularly in underserved areas.
Programs like Gavi, the Vaccine Alliance, are ensuring vaccine access in economically challenged nations.
Public health budgets are being expanded to support vaccine research and production, driving demand for novel adjuvants.

Emerging Opportunities

1. Next-Generation Adjuvants

Pharmaceutical developers are prioritizing advanced adjuvants, such as: Lipid nanoparticles (LNPs) Liposomes Immune modulators
These new formulations are being tailored to optimize immune responses, particularly for emerging infectious diseases.

2. Growth in mRNA Vaccine Applications

mRNA-based vaccines are transforming the vaccine adjuvants Analysis, especially in addressing COVID-19 and beyond.
Lipid nanoparticles (LNPs) play a vital role in efficient mRNA vaccine delivery and immune activation.
In 2024, the U.S. government allocated US$ 590 million to Moderna to expedite the mRNA-based H5N1 avian influenza vaccine.
The increasing implementation of mRNA vaccine strategies for diseases such as influenza, Zika virus, and cancer is expected to bolster the demand for adjuvants.

Regional Market Insights

North America: Market Leader

North America remains at the forefront of the global vaccine adjuvants market, attributed to: Well-developed healthcare infrastructure Robust R&D investments Government-driven immunization policies A strong presence of biotech firms
The region serves as a center for vaccine innovation, with continued efforts in developing superior adjuvants.

Asia Pacific: Rapid Expansion

Asia Pacific is emerging as a dynamic market, driven by: Extensive government-backed vaccination initiatives in China, India, and Japan Rising investments in healthcare Expanding pharmaceutical and biotech sectors High incidence of infectious diseases
The region's large population size and advancing medical infrastructure position it as a critical player in vaccine adjuvant development.

Competitive Analysis

The vaccine adjuvants industry is marked by intense competition, with leading corporations focusing on product innovation and market expansion. Industry players are concentrating on developing advanced adjuvants that enhance vaccine effectiveness.

Key Industry Participants

1. Pfizer Inc.

2. GlaxoSmithKline plc

3. AstraZeneca

4. 3M

5. Merck KGaA

6. Adjuvatis

7. Croda International Plc

8. Novavax, Inc.

9. InvivoGen

10. Phibro Animal Health Corporation

11. SEPPIC

12. Agenus Inc.

Recent Industry Advancements

June 2024 - SPI Pharma, Inc. partnered with Inimmune, Corp. to advance commercialization of new vaccine adjuvant solutions.
March 2024 - Croda International Plc collaborated with the Access to Advanced Health Institute (AAHI) to introduce innovative adjuvant formulations.

Market Segmentation

By Product Type

Adjuvant Emulsions (Projected 30% market share in 2025)
Particulate Adjuvants
Combination Adjuvants
Pathogen Components
Carbohydrate Adjuvants
Liposome Adjuvants
Alum
Others

By Administration Route

Intramuscular
Intranasal
Intradermal
Oral
Subcutaneous
Others

By Disease Focus

Infectious Diseases
Cancer
Others

By Application

Commercial Use
Research Use

By Vaccine Type

Human Vaccine (Projected 70% market share in 2025)
Veterinary Vaccine

By End User

Adults
Pediatric
Others

By Geographical Region

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

1. Executive Summary

1.1. Global Vaccine Adjuvant Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2025
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Price Analysis, 2019 - 2025

3.1. Global Average Price Analysis, by Product Type, US$ Per Unit, 2019 - 2032
3.2. Prominent Factor Affecting Vaccine Adjuvant Prices
3.3. Global Average Price Analysis, by Region, US$ Per Unit

4. Global Vaccine Adjuvant Market Outlook, 2019 - 2032

4.1. Global Vaccine Adjuvant Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 4.1.1. Key Highlights
  - 4.1.1.1. Adjuvant emulsions
  - 4.1.1.2. Particulate adjuvants
  - 4.1.1.3. Combination adjuvants
  - 4.1.1.4. Pathogen components
  - 4.1.1.5. Carbohydrate adjuvants
  - 4.1.1.6. Liposome adjuvants
  - 4.1.1.7. Alum
  - 4.1.1.8. Others
4.2. Global Vaccine Adjuvant Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 4.2.1. Key Highlights
  - 4.2.1.1. Intramuscular Route
  - 4.2.1.2. Intranasal Route
  - 4.2.1.3. Intradermal Route
  - 4.2.1.4. Oral Route
  - 4.2.1.5. Subcutaneous Route
  - 4.2.1.6. Others
4.3. Global Vaccine Adjuvant Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 4.3.1. Key Highlights
  - 4.3.1.1. Cancer
  - 4.3.1.2. Infectious diseases
  - 4.3.1.3. Others
4.4. Global Vaccine Adjuvant Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 4.4.1. Key Highlights
  - 4.4.1.1. Commercial application
  - 4.4.1.2. Research application
4.5. Global Vaccine Adjuvant Market Outlook, by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 4.5.1. Key Highlights
  - 4.5.1.1. Human vaccine
  - 4.5.1.2. Veterinary vaccine
4.6. Global Vaccine Adjuvant Market Outlook, by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 4.6.1. Key Highlights
  - 4.6.1.1. Adults
  - 4.6.1.2. Pediatric
  - 4.6.1.3. Others
4.7. Global Vaccine Adjuvant Market Outlook, by Region, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 4.7.1. Key Highlights
  - 4.7.1.1. North America
  - 4.7.1.2. Europe
  - 4.7.1.3. Asia Pacific
  - 4.7.1.4. Latin America
  - 4.7.1.5. Middle East & Africa

5. North America Vaccine Adjuvant Market Outlook, 2019 - 2032

5.1. North America Vaccine Adjuvant Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 5.1.1. Key Highlights
  - 5.1.1.1. Adjuvant emulsions
  - 5.1.1.2. Particulate adjuvants
  - 5.1.1.3. Combination adjuvants
  - 5.1.1.4. Pathogen components
  - 5.1.1.5. Carbohydrate adjuvants
  - 5.1.1.6. Liposome adjuvants
  - 5.1.1.7. Alum
  - 5.1.1.8. Others
5.2. North America Vaccine Adjuvant Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 5.2.1. Key Highlights
  - 5.2.1.1. Intramuscular route
  - 5.2.1.2. Intranasal route
  - 5.2.1.3. Intradermal route
  - 5.2.1.4. Oral route
  - 5.2.1.5. Subcutaneous route
  - 5.2.1.6. Others
5.3. North America Vaccine Adjuvant Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 5.3.1. Key Highlights
  - 5.3.1.1. Cancer
  - 5.3.1.2. Infectious diseases
  - 5.3.1.3. Others
5.4. North America Vaccine Adjuvant Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 5.4.1. Key Highlights
  - 5.4.1.1. Commercial application
  - 5.4.1.2. Research application
5.5. North America Vaccine Adjuvant Market Outlook, by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 5.5.1. Key Highlights
  - 5.5.1.1. Human vaccine
  - 5.5.1.2. Veterinary vaccine
5.6. North America Vaccine Adjuvant Market Outlook, by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 5.6.1. Key Highlights
  - 5.6.1.1. Adults
  - 5.6.1.2. Pediatric
  - 5.6.1.3. Others
5.7. North America Vaccine Adjuvant Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 5.7.1. Key Highlights
  - 5.7.1.1. U.S. Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 5.7.1.2. U.S. Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 5.7.1.3. U.S. Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 5.7.1.4. U.S. Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 5.7.1.5. U.S. Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 5.7.1.6. U.S. Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 5.7.1.7. Canada Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 5.7.1.8. Canada Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 5.7.1.9. Canada Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 5.7.1.10. Canada Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 5.7.1.11. Canada Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 5.7.1.12. Canada Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032

6. Europe Vaccine Adjuvant Market Outlook, 2019 - 2032

6.1. Europe Vaccine Adjuvant Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 6.1.1. Key Highlights
  - 6.1.1.1. Adjuvant emulsions
  - 6.1.1.2. Particulate adjuvants
  - 6.1.1.3. Combination adjuvants
  - 6.1.1.4. Pathogen components
  - 6.1.1.5. Carbohydrate adjuvants
  - 6.1.1.6. Liposome adjuvants
  - 6.1.1.7. Alum
  - 6.1.1.8. Others
6.2. Europe Vaccine Adjuvant Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 6.2.1. Key Highlights
  - 6.2.1.1. Intramuscular route
  - 6.2.1.2. Intranasal route
  - 6.2.1.3. Intradermal route
  - 6.2.1.4. Oral route
  - 6.2.1.5. Subcutaneous route
  - 6.2.1.6. Others
6.3. Europe Vaccine Adjuvant Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 6.3.1. Key Highlights
  - 6.3.1.1. Cancer
  - 6.3.1.2. Infectious diseases
  - 6.3.1.3. Others
6.4. Europe Vaccine Adjuvant Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 6.4.1. Key Highlights
  - 6.4.1.1. Commercial application
  - 6.4.1.2. Research application
6.5. Europe Vaccine Adjuvant Market Outlook, by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 6.5.1. Key Highlights
  - 6.5.1.1. Human vaccine
  - 6.5.1.2. Veterinary vaccine
6.6. Europe Vaccine Adjuvant Market Outlook, by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 6.6.1. Key Highlights
  - 6.6.1.1. Adults
  - 6.6.1.2. Pediatric
  - 6.6.1.3. Others
6.7. Europe Vaccine Adjuvant Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 6.7.1. Key Highlights
  - 6.7.1.1. Germany Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.2. Germany Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.3. Germany Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.4. Germany Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.5. Germany Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.6. Germany Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.7. Germany Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.8. U.K. Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.9. U.K. Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.10. U.K. Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.11. U.K. Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.12. U.K. Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.13. U.K. Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.14. France Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.15. France Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.16. France Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.17. France Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.18. France Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.19. France Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.20. Italy Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.21. Italy Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.22. Italy Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.23. Italy Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.24. Italy Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.25. Italy Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.26. Turkey Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.27. Turkey Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.28. Turkey Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.29. Turkey Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.30. Turkey Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.31. Turkey Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.32. Russia Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.33. Russia Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.34. Russia Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.35. Russia Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.36. Russia Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.37. Russia Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.38. Rest of Europe Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.39. Rest of Europe Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.40. Rest of Europe Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.41. Rest of Europe Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.42. Rest of Europe Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.7.1.43. Rest of Europe Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032

7. Asia Pacific Vaccine Adjuvant Market Outlook, 2019 - 2032

7.1. Asia Pacific Vaccine Adjuvant Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 7.1.1. Key Highlights
  - 7.1.1.1. Adjuvant emulsions
  - 7.1.1.2. Particulate adjuvants
  - 7.1.1.3. Combination adjuvants
  - 7.1.1.4. Pathogen components
  - 7.1.1.5. Carbohydrate adjuvants
  - 7.1.1.6. Liposome adjuvants
  - 7.1.1.7. Alum
  - 7.1.1.8. Others
7.2. Asia Pacific Vaccine Adjuvant Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 7.2.1. Key Highlights
  - 7.2.1.1. Intramuscular route
  - 7.2.1.2. Intranasal route
  - 7.2.1.3. Intradermal route
  - 7.2.1.4. Oral route
  - 7.2.1.5. Subcutaneous route
  - 7.2.1.6. Others
7.3. Asia Pacific Vaccine Adjuvant Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 7.3.1. Key Highlights
  - 7.3.1.1. Cancer
  - 7.3.1.2. Infectious diseases
  - 7.3.1.3. Others
7.4. Asia Pacific Vaccine Adjuvant Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 7.4.1. Key Highlights
  - 7.4.1.1. Commercial application
  - 7.4.1.2. Research application
7.5. Asia Pacific Vaccine Adjuvant Market Outlook, by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 7.5.1. Key Highlights
  - 7.5.1.1. Human vaccine
  - 7.5.1.2. Veterinary vaccine
7.6. Asia Pacific Vaccine Adjuvant Market Outlook, by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 7.6.1. Key Highlights
  - 7.6.1.1. Adults
  - 7.6.1.2. Pediatric
  - 7.6.1.3. Others
7.7. Asia Pacific Vaccine Adjuvant Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 7.7.1. Key Highlights
  - 7.7.1.1. China Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.2. China Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.3. China Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.4. China Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.5. China Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.6. China Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.7. Japan Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.8. Japan Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.9. Japan Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.10. Japan Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.11. Japan Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.12. Japan Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.13. South Korea Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.14. South Korea Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.15. South Korea Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.16. South Korea Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.17. South Korea Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.18. South Korea Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.19. India Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.20. India Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.21. India Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.22. India Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.23. India Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.24. India Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.25. Southeast Asia Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.26. Southeast Asia Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.27. Southeast Asia Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.28. Southeast Asia Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.29. Southeast Asia Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.30. Southeast Asia Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.31. Rest of Asia Pacific Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.32. Rest of Asia Pacific Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.33. Rest of Asia Pacific Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.34. Rest of Asia Pacific Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.35. Rest of Asia Pacific Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.7.1.36. Rest of Asia Pacific Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032

8. Latin America Vaccine Adjuvant Market Outlook, 2019 - 2032

8.1. Latin America Vaccine Adjuvant Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 8.1.1. Key Highlights
  - 8.1.1.1. Adjuvant emulsions
  - 8.1.1.2. Particulate adjuvants
  - 8.1.1.3. Combination adjuvants
  - 8.1.1.4. Pathogen components
  - 8.1.1.5. Carbohydrate adjuvants
  - 8.1.1.6. Liposome adjuvants
  - 8.1.1.7. Alum
  - 8.1.1.8. Others
8.2. Latin America Vaccine Adjuvant Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 8.2.1. Key Highlights
  - 8.2.1.1. Intramuscular route
  - 8.2.1.2. Intranasal route
  - 8.2.1.3. Intradermal route
  - 8.2.1.4. Oral route
  - 8.2.1.5. Subcutaneous route
  - 8.2.1.6. Others
8.3. Latin America Vaccine Adjuvant Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 8.3.1. Key Highlights
  - 8.3.1.1. Cancer
  - 8.3.1.2. Infectious diseases
  - 8.3.1.3. Others
8.4. Latin America Vaccine Adjuvant Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 8.4.1. Key Highlights
  - 8.4.1.1. Commercial application
  - 8.4.1.2. Research application
8.5. Latin America Vaccine Adjuvant Market Outlook, by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 8.5.1. Key Highlights
  - 8.5.1.1. Human vaccine
  - 8.5.1.2. Veterinary vaccine
8.6. Latin America Vaccine Adjuvant Market Outlook, by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 8.6.1. Key Highlights
  - 8.6.1.1. Adults
  - 8.6.1.2. Pediatric
  - 8.6.1.3. Others
8.7. Latin America Vaccine Adjuvant Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 8.7.1. Key Highlights
  - 8.7.1.1. Brazil Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.2. Brazil Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.3. Brazil Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.4. Brazil Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.5. Brazil Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.6. Brazil Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.7. Mexico Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.8. Mexico Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.9. Mexico Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.10. Mexico Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.11. Mexico Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.12. Mexico Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.13. Argentina Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.14. Argentina Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.15. Argentina Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.16. Argentina Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.17. Argentina Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.18. Argentina Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.19. Rest of Latin America Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.20. Rest of Latin America Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.21. Rest of Latin America Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.22. Rest of Latin America Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.23. Rest of Latin America Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.7.1.24. Rest of Latin America Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032

9. Middle East & Africa Vaccine Adjuvant Market Outlook, 2019 - 2032

9.1. Middle East & Africa Vaccine Adjuvant Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 9.1.1. Key Highlights
  - 9.1.1.1. Adjuvant emulsions
  - 9.1.1.2. Particulate adjuvants
  - 9.1.1.3. Combination adjuvants
  - 9.1.1.4. Pathogen components
  - 9.1.1.5. Carbohydrate adjuvants
  - 9.1.1.6. Liposome adjuvants
  - 9.1.1.7. Alum
  - 9.1.1.8. Others
9.2. Middle East & Africa Vaccine Adjuvant Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 9.2.1. Key Highlights
  - 9.2.1.1. Intramuscular route
  - 9.2.1.2. Intranasal route
  - 9.2.1.3. Intradermal route
  - 9.2.1.4. Oral route
  - 9.2.1.5. Subcutaneous route
  - 9.2.1.6. Others
9.3. Middle East & Africa Vaccine Adjuvant Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 9.3.1. Key Highlights
  - 9.3.1.1. Cancer
  - 9.3.1.2. Infectious diseases
  - 9.3.1.3. Others
9.4. Middle East & Africa Vaccine Adjuvant Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 9.4.1. Key Highlights
  - 9.4.1.1. Commercial application
  - 9.4.1.2. Research application
9.5. Middle East & Africa Vaccine Adjuvant Market Outlook, by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 9.5.1. Key Highlights
  - 9.5.1.1. Human vaccine
  - 9.5.1.2. Veterinary vaccine
9.6. Middle East & Africa Vaccine Adjuvant Market Outlook, by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 9.6.1. Key Highlights
  - 9.6.1.1. Adults
  - 9.6.1.2. Pediatric
  - 9.6.1.3. Others
9.7. Middle East & Africa Vaccine Adjuvant Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 9.7.1. Key Highlights
  - 9.7.1.1. GCC Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.2. GCC Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.3. GCC Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.4. GCC Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.5. GCC Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.6. GCC Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.7. South Africa Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.8. South Africa Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.9. South Africa Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.10. South Africa Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.11. South Africa Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.12. South Africa Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.13. Egypt Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.14. Egypt Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.15. Egypt Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.16. Egypt Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.17. Egypt Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.18. Egypt Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.19. Nigeria Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.20. Nigeria Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.21. Nigeria Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.22. Nigeria Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.23. Nigeria Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.24. Nigeria Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.25. Rest of Middle East & Africa Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.26. Rest of Middle East & Africa Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.27. Rest of Middle East & Africa Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.28. Rest of Middle East & Africa Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.29. Rest of Middle East & Africa Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.7.1.30. Rest of Middle East & Africa Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032

10. Competitive Landscape

10.1. Company Market Share Analysis, 2025
10.2. Competitive Dashboard
10.3. Company Profiles
- 10.3.1. Pfizer Inc.
  - 10.3.1.1. Company Overview
  - 10.3.1.2. Product Portfolio
  - 10.3.1.3. Financial Overview
  - 10.3.1.4. Business Strategies and Development
- 10.3.2. GlaxoSmithKline plc
  - 10.3.2.1. Company Overview
  - 10.3.2.2. Product Portfolio
  - 10.3.2.3. Financial Overview
  - 10.3.2.4. Business Strategies and Development
- 10.3.3. AstraZeneca
  - 10.3.3.1. Company Overview
  - 10.3.3.2. Product Portfolio
  - 10.3.3.3. Financial Overview
  - 10.3.3.4. Business Strategies and Development
- 10.3.4. 3M
  - 10.3.4.1. Company Overview
  - 10.3.4.2. Product Portfolio
  - 10.3.4.3. Financial Overview
  - 10.3.4.4. Business Strategies and Development
- 10.3.5. Merck KGaA
  - 10.3.5.1. Company Overview
  - 10.3.5.2. Product Portfolio
  - 10.3.5.3. Financial Overview
  - 10.3.5.4. Business Strategies and Development
- 10.3.6. Adjuvatis
  - 10.3.6.1. Company Overview
  - 10.3.6.2. Product Portfolio
  - 10.3.6.3. Financial Overview
  - 10.3.6.4. Business Strategies and Development
- 10.3.7. Croda International Plc
  - 10.3.7.1. Company Overview
  - 10.3.7.2. Product Portfolio
  - 10.3.7.3. Financial Overview
  - 10.3.7.4. Business Strategies and Development
- 10.3.8. Novavax, Inc.
  - 10.3.8.1. Company Overview
  - 10.3.8.2. Product Portfolio
  - 10.3.8.3. Financial Overview
  - 10.3.8.4. Business Strategies and Development
- 10.3.9. InvivoGen
  - 10.3.9.1. Company Overview
  - 10.3.9.2. Product Portfolio
  - 10.3.9.3. Financial Overview
  - 10.3.9.4. Business Strategies and Development
- 10.3.10. Phibro Animal Health Corporation
  - 10.3.10.1. Company Overview
  - 10.3.10.2. Product Portfolio
  - 10.3.10.3. Financial Overview
  - 10.3.10.4. Business Strategies and Development
- 10.3.11. SEPPIC
  - 10.3.11.1. Company Overview
  - 10.3.11.2. Product Portfolio
  - 10.3.11.3. Financial